Signals mentioning API Holdings
- PharmEasy parent API Holdings' $1B-$1.2B IPO target resurfaces from May 2021
- PharmEasy rights issue signals valuation plunge from 2021 peak
- PharmEasy's 2021 plan targeted $9 billion valuation in $1 billion IPO
- PharmEasy's ₹2,400 crore rights issue to repay debt resurfaces from July 2023
- Resurfacing a June 2021 move: PharmEasy parent API Holdings bought 66.1% of Thyrocare for ₹4,546 crore
- API Holdings repays ₹1,050 crore debt, releases pledge on Thyrocare stake
- PharmEasy parent API Holdings repays ₹1,050 crore debt, turns debt-free
- PharmEasy weighs renewed IPO bid as valuation resets to $2.7 billion
- Thyrocare falls 7.8% after promoter sells 9.9% stake despite strong Q1 growth
- PharmEasy reverse merger hinges on API Holdings turning debt-free and profitable
- Chemists strike against e-pharmacies as 2018 rules lapse, leaving PharmEasy in regulatory limbo
- PharmEasy parent API Holdings pulls IPO, pivots to rights issue for growth funding
- PharmEasy parent API Holdings pulls Rs 6,250 cr IPO, weighs rights issue from Prosus, TPG, Temasek
- PharmEasy parent API Holdings withdraws Rs 6,250 cr DRHP, eyes rights issue